DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Carboplatin (Carboplatin) - Summary


Carboplatin injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available.

Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug related side effect.

Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of carboplatin injection administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.



Carboplatin injection is supplied as a sterile, pyrogen-free, 10 mg/mL aqueous solution of carboplatin, USP. Carboplatin, USP is a platinum coordination compound.

Initial Treatment of Advanced Ovarian Carcinoma

Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES Secondary Treatment of Advanced Ovarian Carcinoma

Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.

Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.

See all Carboplatin indications & dosage >>


Media Articles Related to Carboplatin

Chemotherapy-induced hearing loss affects cognition in pediatric brain tumor survivors
Source: Hearing / Deafness News From Medical News Today [2015.11.05]
More children are surviving malignant brain tumors than in the past, thanks to the use of intense treatments using platinum-based chemotherapy (cisplatin and high-dose carboplatin).

Researchers find experimental drug can help fight debilitating side effect of ovarian cancer
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2015.11.17]
UCLA team finds new way to reduce painful, common condition called ascitesWomen who have ovarian cancer often develop a condition called ascites, which is a buildup of fluids in the abdomen.

Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
Source: Medical Devices / Diagnostics News From Medical News Today [2015.11.17]
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.

Healthy diet may reduce risk of ovarian cancer in African-American women
Source: Nutrition / Diet News From Medical News Today [2015.11.16]
A healthy diet may reduce the risk of ovarian cancer in African-American women, according to data presented at the Eighth American Association for Cancer Research (AACR) Conference on the Science of...

Healthy Diet May Lower Black Women's Risk of Ovarian Cancer
Source: MedicineNet Ovarian Cancer Specialty [2015.11.13]
Title: Healthy Diet May Lower Black Women's Risk of Ovarian Cancer
Category: Health News
Created: 11/13/2015 12:00:00 AM
Last Editorial Review: 11/13/2015 12:00:00 AM

more news >>

Published Studies Related to Carboplatin

In vivo intraocular distribution and safety of periocular nanoparticle carboplatin for treatment of advanced retinoblastoma in humans. [2014]
DESIGN: Prospective, interventional, comparative case series... CONCLUSION: Results may indicate an increased facilitated trans-scleral transport

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. [2014]
potential, when combined with weekly AUC2-carboplatin in PROC patients... CONCLUSIONS: Orally delivered PXD showed no evidence of clinical activity, when

Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer. [2013]
diagnosed advanced ovarian cancer... CONCLUSION: The PCE combination increased PFS, but it was not significantly

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. [2013]
metastatic melanoma... CONCLUSION: Sorafenib does not improve OS when given in combination with CP for

A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). [2013]
xenograft models of human ovarian cancer... CONCLUSIONS: Zibotentan 10mg/day plus carboplatin and paclitaxel did not result

more studies >>

Clinical Trials Related to Carboplatin

Trientine and Carboplatin in Advanced Malignancies [Completed]
The goal of this clinical research study is to find the highest tolerable dose of the combination of trientine and carboplatin that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors [Recruiting]
The purpose of this study is to find out the good and bad effects that occur when BKM120 is added to standard chemotherapy with carboplatin and paclitaxel.

Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer [Recruiting]
This phase I trial studies the side effects and best dose of heated carboplatin given into the abdomen at the time of surgery in treating patients with stage II-IV ovarian, fallopian tube, or peritoneal cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating oxaliplatin and infusing it directly into the area around the tumor during surgery may kill more tumor cells.

Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) [Recruiting]
The primary objective of this study is to compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15 intraductal infusion. Secondary objectives are to characterize the biologic and clinical effects with respect to: pharmacokinetics, extent of disease on MRI and mammogram, histopathological assessment of DCIS, and biomarker measurement of Ki-67, TUNEL and G-actin.

Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel [Recruiting]
An Open-label Phase 1b Study of ARQ 092 in Combination with Carboplatin Plus Paclitaxel in Subjects with Selected Solid Tumors

more trials >>

Reports of Suspected Carboplatin Side Effects

Vomiting (245)Nausea (244)Diarrhoea (237)Anaemia (233)Neutropenia (217)Febrile Neutropenia (206)Dyspnoea (202)Dehydration (166)Fatigue (165)Pyrexia (141)more >>

Page last updated: 2015-11-17

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015